Cochrane · systematic review · CD012956
Pharmacological interventions for people with borderline personality disorder
Stoffers-Winterling, JM, Storebø, OJ, Pereira Ribeiro, J, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
20
No studies
1
Included studies
NR
No studies 1 · 4.8%Ungraded 0 · 0%Very low 16 · 76.2%Low 4 · 19%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antipsychotics compared with placebo for people with borderline personality disorder
Population: people with borderline personality disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
BPD symptom severity Timing of outcome assessment: end of treatment (5 to 12 weeks treatment duration) Antipsychotics vs placebo | no estimate extracted | 8 studies · 951 participants | Very low Downgraded: risk of bias |
Self‐harm Timing of outcome assessment: end of treatment (8 to 24 weeks treatment duration) Antipsychotics vs placebo | RR 0.66 | 2 studies · 76 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) Antipsychotics vs placebo | no estimate extracted | 7 studies · 854 participants | Very low Downgraded: risk of bias |
Psychosocial functioning Timing of outcome assessment: end of treatment (5 to 12 weeks treatment duration) Antipsychotics vs placebo | no estimate extracted | 7 studies · 904 participants | Very low Downgraded: risk of bias |
Interpersonal problems Timing of outcome assessment: end of treatment (5 to 12 weeks treatment duration) Antipsychotics vs placebo | no estimate extracted | 8 studies · 907 participants | Low Downgraded: risk of bias |
Attrition Timing of outcome assessment: end of treatment (5 weeks to 6 months treatment duration) Antipsychotics vs placebo | RR 1.11 | 13 studies · 1216 participants | Very low Downgraded: risk of bias |
Non‐serious adverse events Timing of outcome assessment: end of treatment (8 to 12 weeks treatment duration) Antipsychotics vs placebo | RR 1.07 | 5 studies · 814 participants | Very low Downgraded: risk of bias |
Antidepressants compared with placebo for people with borderline personality disorder
Population: people with borderline personality disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
BPD symptom severity Timing of outcome assessment: end of treatment (5 to 6 weeks treatment duration) Antidepressants vs placebo | no estimate extracted | 2 studies · 87 participants | Very low Downgraded: imprecision |
Self‐harm Antidepressants vs placebo | no estimate extracted | 1 study · 20 participants | Very low Downgraded: imprecision |
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) Antidepressants vs placebo | no estimate extracted | 2 studies · 45 participants | Very low Downgraded: imprecision |
Psychosocial functioning Timing of outcome assessment: end of treatment (5 to 12 weeks treatment duration) Antidepressants vs placebo | no estimate extracted | 4 studies · 161 participants | Very low Downgraded: imprecision |
Interpersonal problems Timing of outcome assessment: end of treatment (5 weeks treatment duration) Antidepressants vs placebo | no estimate extracted | 2 studies · 119 participants | Very low Downgraded: imprecision |
Attrition Timing of outcome assessment: end of treatment (5 weeks to 6 months treatment duration) Antidepressants vs placebo | RR 1.07 | 6 studies · 289 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Non‐serious adverse events Timing of outcome assessment: end of treatment Antidepressants vs placebo | no estimate extracted | NR | No studies |
Mood stabilisers compared with placebo for people with borderline personality disorder
Population: people with borderline personality disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
BPD symptom severity Timing of outcome assessment: end of treatment (6 to 52 weeks treatment duration) Mood stabilisers vs placebo | no estimate extracted | 4 studies · 265 participants | Very low Downgraded: risk of bias, imprecision |
Self‐harm Timing of outcome assessment: end of treatment (52 weeks treatment duration) Mood stabilisers vs placebo | RR 1.08 [0.79, 1.48] | 1 study · 276 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 10 weeks treatment duration) Mood stabilisers vs placebo | no estimate extracted | 2 studies · 44 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Psychosocial functioning Timing of outcome assessment: end of treatment (32 days to 6 weeks treatment duration) Mood stabilisers vs placebo | no estimate extracted | 2 studies · 214 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) Mood stabilisers vs placebo | no estimate extracted | 4 studies · 300 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Attrition Timing of outcome assessment: end of treatment (32 days to 24 weeks treatment duration) Mood stabilisers vs placebo | RR 0.89 | 9 studies · 530 participants | Low Downgraded: risk of bias |
Non‐serious adverse events Timing of outcome assessment: end of treatment (6 weeks treatment duration) Mood stabilisers vs placebo | RR 0.84 | 1 study · 276 participants | Very low Downgraded: risk of bias |